Modified CRISPR technique used to combat Parkinson’s disease
Biological engineers identify genes that protect against protein linked to Parkinson's disease...
List view / Grid view
Biological engineers identify genes that protect against protein linked to Parkinson's disease...
Researchers have found that polymer and hybrid silica-coated microcapsules are efficient in genome-editing...
A new technique for modelling leukaemia may aid drug discovery...
Researchers have used CRISPR-Cas9 to inactivate genes in human colorectal cancer cell lines -- one with normal KRAS gene and one with a mutant KRAS...
Researchers have used genome editing technology to reveal the role of a key gene in human embryos in the first few days of development...
A team of researchers has identified the mutated gene GREB1L is linked to renal agenesis...
Researchers have developed a method, based on CRISPR-Cas9 technology in organoids, to study the genetic cause of hereditary forms of cancer...
Assay robustness tends to be the favoured descriptor when a particular assay can cope with minute changes in the sample, equipment, or operator. The more robust an assay, the more predictive data it ultimately yields. The industry’s greatest challenge for assay development has always been using those robust assays to…
Researchers have used a modified version of the gene-editing technique CRISPR in search for gene activators...
Scientists have developed an innovative system to identify and characterise the molecular components that control the activities of regulatory DNA sequences...
Researchers have used CRISPR to stop the expression of individual genes in cancer cells, by knocking out every known protein-encoding gene in the human genome...
"Well thought through and brilliantly executed" study shows different DNA-repair mechanism in embryos compared to iPSCs
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
Human induced pluripotent stem cell derived macrophages (iPSDMs) provide a cell-based model system to study chlamydia infection in the laboratory. Amy Yeung from Wellcome Trust Sanger Institute explains how she used this model in combination with CRISPR-Cas 9 technology to explore the potential of the two genes, IRF5 and IL10RA,…
As CRISPR-Cas9 starts to move into clinical trials, a new study has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.